secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zai Lab Ltd (ZLAB)
CIK:        0001704292
Form:       8-K
Filed at:   2023-01-09T23:59:59+00:00
Accession:  0001628280-23-000722
Event type: leadership
Sentiment:  neutral
Materiality: 0.45
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zai Lab appoints former Biogen CEO Michel Vounatsos as independent director
---------------------------------------------------------------------------

- Appointed Michel Vounatsos independent director effective Jan 7, 2023; chairs Commercial Committee and serves on R&D.
- Vounatsos was Biogen CEO (2017-2022) and previously President of MSD China; brings global and China commercial expertise.
- Compensation: $50k annual retainer, $15k for Commercial chair, $7.5k for R&D; restricted shares $750k vesting over 3 years.
- Press release notes Zai Lab has four marketed medicines and plans three more launches in near term.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1704292/000162828023000722/0001628280-23-000722-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1704292/000162828023000722/zlab-20230107.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-000722

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer